Beyond Air, Inc. (XAIR) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended December 31, 2025 (Q3 2025). Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing the LungFit® platform, which generates nitric oxide (NO) from ambient air. The company's primary commercial product, LungFit® PH, received FDA approval in 2022 and CE mark approval in late 2024 for treating pulmonary hypertension in neonates and peri-operative patients. The company also operates two subsidiaries: Beyond Cancer (oncology) and NeuroNos (neurology/ASD).
Capital Structure Note: A 1-for-20 reverse stock split was effectuated on July 14, 2025. All share and per-share data in this filing have been retroactively adjusted.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues | $2,194 | $1,072 | $5,772 | $2,553 |
| Gross Profit | $300 | $(215) | $158 | $(1,631) |
| Net Loss (Attributable to BA) | $(7,336) | $(13,032) | $(22,967) | $(38,591) |
| Loss Per Share (Basic/Diluted) | $(0.85) | $(2.96) | $(3.44) | $(12.77) |
| Cash & Cash Equivalents | $6,643 | $4,665 | $6,643 | $4,665 |
| Marketable Securities | $5,018 | $2,252 | $5,018 | $2,252 |
| Restricted Cash | $6,187 | $231 | $6,187 | $231 |
| Total Debt (Long-term, net) | $21,974 | $9,197 | $21,974 | $9,197 |
Liquidity Position: As of December 31, 2025, the company held approximately $11.7 million in cash, cash equivalents, and marketable securities. Additionally, $6.2 million of cash is restricted (held by a contract manufacturer or in a restricted account related to a promissory note).
Material Changes vs. Prior Period
- Revenue Growth: Revenue for the three months ended December 31, 2025, increased 105% year-over-year to $2.2 million, driven by new hospital contracts and international market expansion. Gross profit turned positive ($300k) compared to a loss of $215k in the prior year.
- Expense Reduction: Operating expenses decreased significantly. R&D expenses dropped 19% ($2.4M vs $3.0M) and SG&A expenses dropped 42% ($4.5M vs $7.7M) compared to Q3 2024, primarily due to reduced salaries, lower stock-based compensation, and decreased professional fees.
- Debt Increase: Long-term debt increased from $9.2 million to $22.0 million. This reflects a new $12.0 million secured promissory note with Streeterville Capital (Nov 2025) and amendments to existing loan agreements.
- Stock-Based Compensation: Total stock-based compensation expense for the nine months ended Dec 31, 2025, was $4.9 million, down from $9.0 million in the prior year period.
Outlook, Risks, and Subsequent Events
Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional funding. The company expects to incur net losses and cash outflows for at least the next year.
Recent Financing (Subsequent Events):
- January 2026 Private Placement: The company entered into a securities purchase agreement to raise $5.0 million in gross proceeds via common stock, pre-funded warrants, and common warrants. The offering closed on January 16, 2026.
- Streeterville Note: In January 2026, Streeterville elected to purchase 1.6 million shares of common stock, offsetting approximately $1.2 million of the outstanding note principal and releasing $0.6 million of restricted cash.
Strategic Developments:
- NeuroNos Sale: On January 8, 2026, the company entered into a letter of intent to sell its 85% ownership interest in NeuroNos to XTL Biopharmaceuticals Ltd. for cash, equity, and contingent milestone payments totaling up to $31.5 million. No definitive agreement has been signed.
- ATM Limitations: Due to SEC "baby shelf rules" (public float under $75 million), the company is currently unable to sell shares under its At-The-Market (ATM) facility until its public float increases.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $5.0 million raised in January 2026 against the company's stated need for additional funding within one year.
- NeuroNos Transaction: Monitor the status of the definitive agreement for the sale of NeuroNos to XTL Biopharmaceuticals, as failure to close could impact strategic direction and valuation.
- Debt Covenants & Interest: Review the terms of the Streeterville Note (15% interest, 24-month maturity) and the Loan Agreement (15% interest, 8% royalty on net sales starting July 2026) to assess future cash flow obligations.
- Revenue Sustainability: Assess the durability of the 105% revenue growth, noting that gross margins remain thin (approx. 14% for Q3) and are sensitive to device upgrade costs and inventory provisions.
- ATM Availability: Confirm if the company's public float has exceeded $75 million to unlock the $35 million ATM facility with BTIG.